Skip to content
Screener

CytomX Therapeutics CTMX Total Operating Expenses

Total Operating Expenses at other companies

Immunome logo
ImmunomeIMNM
$78.14M+54.7%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$137M-18.5%
CTO
Citius Oncology, Inc.CTOR
$29.95M+301%

Other financials

Income statement

See full
Revenue$1.4M-92.4%
Operating income-$23.8M-1,749%
Net income-$20.7M-13,319%
EPS (diluted)-$0.09

Balance sheet

See full
Cash & equivalents$17.2M-64.9%
Total debt$5.7M-17.2%
Total equity$302.1M+152%
Total assets$381.2M+118%

Cash flow

See full
Operating cash flow-$18.1M-14.7%
CapEx--100%
Free cash flow-$18.1M-14.5%

Valuation

See full
Market cap$749.57M+96.8%
Enterprise value$738.05M+118%
P/S41×+38.3×

Profitability

See full
Operating margin-476.2%-507pp
Net margin-435.2%-469pp
FCF margin-450.7%-524pp

Returns & leverage

See full
Return on equity-37.8%
Debt / equity0.0×
Current ratio9.4×+5.2×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337950
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Operating expenses:
Research and development17,59813,32236,83632,189
General and administrative7,6016,62218,29416,050
Total operating expenses25,19919,94455,13048,239
Income (loss) from operations(23,781)(1,286)(43,453)21,336
Interest income3,1571,1784,6472,133
Other income18171128
Income (loss) before income taxes(20,606)(91)(38,795)23,497

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is CytomX Therapeutics's total operating expenses?
CytomX Therapeutics (CTMX) reported total operating expenses of $25.2M in Q2 2026.
How has CytomX Therapeutics's total operating expenses changed year-over-year?
CytomX Therapeutics's total operating expenses increased by 26.3% year-over-year, from $19.94M to $25.2M.
What is the long-term trend for CytomX Therapeutics's total operating expenses?
Over 4 years (2021 to 2025), CytomX Therapeutics's total operating expenses has grown at a -10.5% compound annual growth rate (CAGR), from $153.35M to $98.57M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about CytomX Therapeutics's total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude